The SUMMIT trial, involving 731 individuals with HFpEF and obesity followed for a median of 104 weeks, revealed a 38% decrease in the composite endpoint of cardiovascular mortality or heart-failure deterioration events (HR: 0.62, 95%CI: 0.41-0.95, P = 0.026), driven primarily by fewer worsening heart-failure events (8.0% vs
Use simple tools: periodic bioelectrical impedance, skinfold measures, or DEXA if available
Billing: Immediately, the providers screen shows PA Request: Submitted with a reference ID
Ingredients : L-Tyrosine 31%, capsule shell [glatine, agent d'enrobage (gomme laque), colorant (oxydes et hydroxydes de fer), rgulateurs d'acidit (hydroxyde d'ammonium, hydroxyde de potassium)], Garcinia cambogia fruit extract 16%, L-Carnitine-L-Tartrate 16%, caffeine anhydrous 9%, forskholine root extract (Coleus forskohlii) 6%, bulking agent (cellulose gel), anti-caking agent (magnesium salts of fatty acids)
While tirzepatide's cardiovascular outcomes data are still emerging, its dual incretin action offers a therapeutic profile for metabolic disease management